

Treatment Naïve, Chronic HCV and HIV

Peginterferon alfa-2b + RBV *versus* Interferon alfa-2b
RIBAVIC STUDY


Carrat F, et. al. JAMA. 2004;292:2839-48.

Peginterferon + RBV *versus* Interferon + RBV in HCV & HIV

RIBAVIC Study: Design

- **Study**
 - Randomized, phase 3, open-label, parallel group trial
 - Conducted at 71 French centers
- **Subjects**
 - N = 412 chronically infected with both HCV and HIV
 - Treatment naïve; 48% genotype 1
 - CD4 >200 cells/mm³
- **Regimens (48 Week Treatment)**
 - Peginterferon alfa-2b 1.5 µg 1x/week + Ribavirin 800 mg/day
 - Interferon alfa-2b: 3 million IU 3x/week + Ribavirin 800 mg/day
- **Primary Endpoint**
 - Undetectable serum HCV RNA 24 weeks after stopping treatment

Peginterferon + RBV *versus* Interferon + RBV in HCV & HIV RIBAVIC Study: Design



Drug Dosing


Peginterferon alfa-2b: 1.5 μ g/kg 1x/week

Standard Interferon alfa-2b 3 million units 3x/week

Ribavirin (divided bid): 800 mg/day

Peginterferon + RBV *versus* Interferon + RBV in HCV & HIV RIBAVIC Study: Design

RIBAVIC Study: SVR24 by Treatment Regimen and Genotype



Peginterferon + RBV *versus* Interferon + RBV in HCV & HIV RIBAVIC Study: Conclusions

Conclusion: “In combination with ribavirin, treatment with peginterferon alfa-2b is more effective than standard interferon alfa-2b for HCV infection in HIV-infected patients.”

This slide deck is from the University of Washington's *Hepatitis C Online* and *Hepatitis Web Study* projects.

Hepatitis C Online

www.hepatitisc.uw.edu

Hepatitis Web Study

<http://depts.washington.edu/hepstudy/>

Funded by a grant from the Centers for Disease Control and Prevention.